QT Prolongation Trial For All Drugs Recommended By ICH Draft Guidance
Executive Summary
All drugs should undergo a single cardiac QT interval prolongation trial early in development, an International Conference on Harmonization draft guidance on clinical evaluation of QT prolongation, released Sept. 13, states
You may also be interested in...
QTc Draft Guidance For Non-Antiarrhythmic Drugs: ‘Reasonable Evidence’ Of Causal Cardiac Events Should Result In Boxed Warning
US FDA’s labeling guidance also outlines a number of steps sponsors should take to prevent or mitigate risks associated with QTc interval prolongation.
FDA Seeks Specificity Over Sensitivity To ID Potentially Proarrhythmic Drugs
The agency is looking at preclinical measurement of a drug’s effect on multiple ion channels, in silico modeling and stem cell assays as a possible alternative to “thorough” QT tests to assess the therapy’s impact on heart rhythm.
FDA Seeks Alternatives To QT Interval For Assessing Risk Of Torsade de Pointes
A clinical study funded by the Critical Path Initiative is looking at the change in a number of electrocardiogram parameters in patients given drugs known to prolong the QT interval and with varying risks for the abnormal heart rhythm.